Gladys’ Health: Alzheimer’s

1999 – Diagnosed with COPD

2010 – Cognitive changes – diagnosed with Alzheimer’s disease

2015 – Oxygen therapy for COPD

2018 – Health and wellbeing deteriorated – placed in LTC facility

2019 – Dies due to complications of Alzheimer’s disease

Causes of Alzheimer’s Disease

People with AD gradually suffer memory loss and a decline in thinking abilities, as well as major personality changes. These losses in cognitive function are accompanied by changes in the brain, including the build-up of amyloid plaques and tau-containing neurofibrillary tangles, which result in the death of brain cells and the breakdown of the connections between them.

A diagram showing healthy neurons vs diseased neurons

A healthy brain on the left, versus a brain with severe Alzheimer's Disease on the right

Amyloid plaques and neurofibrillary tangles are the primary hallmarks of Alzheimer’s disease. Plaques are dense deposits of protein and cellular material outside and around the brain’s nerve cells. Tangles are twisted fibers that build up inside the nerve cells. Scientists have known about plaques and tangles since 1906, when a German physician, Dr. Alois Alzheimer, first identified them in the brain of woman who had died after suffering paranoid delusions and psychosis.

PET scans showing the differences between a normal older adult’s brain and the brain of an older adult with Alzheimer’s disease.

Personality and Behaviour Changes

Common Changes in Personality & Behaviour

  • Getting upset, worried, and angry more easily
  • Acting depressed or not interested in things
  • Hiding things or believing other people are hiding things
  • Imagining things that aren’t there
  • Wandering away from home
  • Pacing a lot
  • Showing unusual sexual behaviour
  • Hitting others
  • Misunderstanding what they see or hear
  • Stops caring about how they look

Managing Personality Changes

  • Keep things simple; Ask or say one thing at a time
  • Have a daily routine
  • Reassurance that they are safe and you are there to help
  • Focus on their feelings rather than their words
  • Don’t argue or try to reason with them
  • Try not to show frustration or anger
  • Use humor when appropriate
  • Allow a safe environment for pacing
  • Try using music, singing, or dancing for distraction
  • Ask them to help (“let’s set the table” or “I need help folding the clothes”)

Changes in Communication Skills

Persons with Alzheimer’s may have problems with:

  • Finding the right word or losing their train of thought when speaking
  • Understanding what words mean
  • Paying attention during long conversations
  • Remembering the steps in common activities
  • Blocking out background noises
  • Frustration if communication is not working
  • Being very sensitive to the tone and loudness of voices

Making Communication Easier

Understand that Alzheimer’s causes changes in communication skills.

Try some tips that may make communication easier:

  • Make eye contact and use their name
  • Beware of your tone, loudness of voice, and body language
  • Encourage two-way conversation for as long as possible
  • Use other methods besides speaking, such as gentle touch
  • Try distraction if communication creates problems
  • Be patient
  • Offer simple step-by-step instructions
  • Try not to interrupt
  • Don’t talk to the person using “baby talk” or a “baby voice”

Medications

 

Drug Name Drug Type & Use How It Works Common Side Effects Manufacturer’s Recommended Dosage
Aricept® (donepezil) Cholinesterase inhibitor prescribed to treat symptoms of mild, moderate, and severe Alzheimer’s Prevents the breakdown of acetylcholine in the brain Nausea, vomiting, diarrhea, muscle cramps, fatigue, weight loss
  • Tablet*: Initial dose of 5 mg once a day; may increase dose to 10 mg/day after 4-6 weeks if well tolerated, then to 23 mg/day after at least 3 months
  • Orally disintegrating tablet*: Same dosage as above (not available in 23 mg)
Exelon® (rivastigmine) Cholinesterase inhibitor prescribed to treat symptoms of mild to moderate Alzheimer’s (patch is also for severe Alzheimer’s) Prevents the breakdown of acetylcholine and butyrylcholine (a brain chemical similar to acetylcholine) in the brain Nausea, vomiting, diarrhea, weight loss, indigestion, muscle weakness
  • Capsule*: Initial dose of 3 mg/day (1.5 mg twice a day); may increase dose to 6 mg/day (3 mg twice a day), 9 mg/day (4.5 mg twice a day), and 12 mg/day (6 mg twice a day) at minimum 2-week intervals if well tolerated
  • Patch*: Initial dose of 4.6 mg once a day; may increase dose to 9.5 mg once a day and 13.3 mg once a day at minimum 4-week intervals if well tolerated
Namenda® (memantine) N-methyl D-aspartate (NMDA) antagonist prescribed to treat symptoms of moderate to severe Alzheimer’s Blocks the toxic effects associated with excess glutamate and regulates glutamate activation Dizziness, headache, diarrhea, constipation, confusion
  • Tablet*: Initial dose of 5 mg once a day; may increase dose to 10 mg/day (5 mg twice a day), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice a day) at minimum 1-week intervals if well tolerated
  • Oral solution*: Same dosage as above
  • Extended-release capsule*: Initial dose of 7 mg once a day; may increase dose to 14 mg/day, 21 mg/day, and 28 mg/day at minimum 1-week intervals if well tolerated
Namzaric® (memantine and donepezil) NMDA antagonist and cholinesterase inhibitor prescribed to treat symptoms of moderate to severe Alzheimer’s Blocks the toxic effects associated with excess glutamate and prevents the breakdown of acetylcholine in the brain Headache, nausea, vomiting, diarrhea, dizziness, anorexia
  • Extended-release capsule*: Initial dose of 28 mg memantine/10 mg donepezil once a day if stabilized on memantine and donepezil
  • If stabilized on donepezil only, initial dose of 7 mg memantine/10 mg donepezil once a day; may increase dose to 28 mg memantine/10 mg donepezil in 7 mg increments at minimum 1-week intervals if well tolerated
  • Only 14 mg memantine/10 mg donepezil and 28 mg memantine/10 mg donepezil available as generic
Razadyne® (galantamine) Cholinesterase inhibitor prescribed to treat symptoms of mild to moderate Alzheimer’s Prevents the breakdown of acetylcholine and stimulates nicotinic receptors to release more acetylcholine in the brain Nausea, vomiting, diarrhea, decreased appetite, dizziness, headache
  • Tablet*: Initial dose of 8 mg/day (4 mg twice a day); may increase dose to 16 mg/day (8 mg twice a day) and 24 mg/day (12 mg twice a day) at minimum 4-week intervals if well tolerated
  • Extended-release capsule*: Same dosage as above but taken once a day

DNR and DNH Orders

  • Ontario nursing home DNR & DNH orders reduce inappropriate hospitalizations, but not entirely
  • 3 in 5 nursing home residents had a DNR recorded on admission (Do Not Resuscitate)
  • 1 in 7 had a DNH (Do Not Hospitalize)
  • Residents with a DNR or DNH were less likely to experience hospitalization or in-hospital death

Hospitalization:

  • DNR: 13% less likely
  • DNH: 30% less likely

In-hospital death:

  • DNR: 40% less likely
  • DNH: 60% less likely

 

License

Icon for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

Multi-Course Case Studies in Health Sciences Copyright © 2021 by Laura Banks; Brenda Barth; Robert Balogh; Adam Cole; Mika Nonoyama; Elita Partosoedarso; and Otto Sanchez is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, except where otherwise noted.

Share This Book